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INTRODUCTION
Since its discovery in the late 1980s 1,2, hepatocyte
growth factor (HGF) has been under intense investi-
gation for its role in cancer. Hepatocyte growth fac-
tor has been established as a mitogen that regulates
cell growth and death, a motogen that stimulates cell
motility, a morphogen that modulates cell morphol-
ogy and tissue or organ regeneration, and an angio-
genic factor that induces angiogenesis 2,3 and, as
recently reported, lymphangiogenesis 4,5.
These diverse functions of HGF and of its recep-
tor cMet 3,6 have stimulated additional clinical inter-
est because of their prognostic aspect and the
therapeutic implications of their potential as imaging
tools. Some of the recent discoveries have strongly
indicated the value of both HGF and its receptor in
clinical settings.
EXPRESSION OF HGF AND ITS RECEPTOR IN
CANCER
Hepatocyte growth factor—and particularly the HGF
receptor—has been found to be over-expressed at the
mRNA and protein levels in virtually all human solid
tumours, as well as in hematopoietic-derived malig-
nancies (for a fuller list, see reference 3). Tradition-
ally, HGF was regarded as a protein product from
stromal cells in the body 2. The finding that cancer
cells from epithelial origins show aberrant HGF tran-
scripts and proteins is interesting and indicates that
the source of HGF in the body is well beyond stro-
mal. The discovery of transcription activation of HGF
in epithelial-originated cancer cells, thought to occur
through the cSrc and Stat3 pathways 7, comes in ad-
dition to the knowledge that stromal cells in tumour
tissues overexpress the HGF transcript and HGF pro-
tein. Together with overexpressed HGF receptor on
cancer cells, this situation creates a two-way stimu-
lation for cancer cells: paracrine stimulation (HGF
generated by stromal cells) and autocrine stimula-
tion (HGF generated by cancer cells themselves). In
general, paracrine stimulation is the stronger of the
two in cancer, because a good number of tumour cell
types are known never to express HGF.
The HGF receptor cMet is typically overex-
pressed in cancer cells and in tumour tissues in epi-
thelial-derived tumour types, as well as in stromal
and interstitial cell–derived tumours such as fibrosa-
rcoma and other sarcoma types. An interesting find-
ing in recent years was the discovery that, against
the conventional prediction that hematopoietic-de-
rived cells did not have the receptor, hematopoietic
cells and the malignancies derived from those cells
also express the HGF receptor. These sarcoma and
hematopoietic malignant cells are, to some degree,
dependent on HGF signalling for survival.
Interestingly, although the HGF receptor is a rela-
tively large protein encoded by a large gene (the met
proto-oncogene), genetic analyses have so far pro-
vided little information about mutation of the gene.
A few reports have been published on somatic muta-
tions, but few of those mutations are functional 8. It
is therefore anticipated that aberration of the HGF
receptor is largely a transcriptional event and may
also occur at the post-translational level. However,
some early evidence indicates that functional muta-
tions might in fact be occurring—for example, in lym-
phoma cells 9. This pattern is unlikely to be a
dominating one in cancer cells, and further studies
are needed for clarification.
Thus, the combination of co-expression of HGF
and its receptor, overexpression of the HGF recep-
tor, and elevated levels of bioactive HGF in the tu-
mour or circulation, or both, are frequent events in
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malignancies. Strong clinical evidence has showed
that this overexpression or high levels of the cytokine
and its receptor are intimately linked to disease pro-
gression and, in some cases, to clinical outcomes.
Interestingly, HGF and its receptor, when co-ex-
pressed in the same cancer cells, predict a more viru-
lent and aggressive tumour type 10.
HGF AND cMet SIGNALLING, AND HGF-
REGULATED GENES IN CANCER
Coupling of HGF to its receptor elicits a number of
biochemical events within cells that ultimately lead
to the cellular functions that are observed with HGF.
These events are attributable to a number of path-
ways that are clearly downstream of the HGF recep-
tor. The well-established pathways include the Rho/
Rac pathway, the phosphoinositide 3 kinase pathway,
Wnt signalling, the Grb2 pathway, b-catenin–medi-
ated pathways, and a few other pathways yet to be
confirmed.
These pathways lead to the various effects of HGF
on diverse cell- and tumour-type combinations. They
are not unique to HGF stimulation, but they repre-
sent an impressive collection of cellular events with
resulting aggressive behaviour of cancer cells,
whether that behaviour be growth, migration, inva-
sion, or other functions. Furthermore, HGF is among
the most aberrant cytokines present in tumours. Thus,
the HGF complex in cancer mimics, in some aspect,
the classical cytokine–receptor complex abnormali-
ties in cancer: aberrant levels of cytokine coupled
with overexpressed HGF receptor and auto-activated
receptor signalling pathways.
Genes that are specifically upregulated by the
HGF–cMet activation were relatively less known until
a recent microarray-based analysis of an HGF- and
met-deleted transgenic mouse 11. A combined HGF
and met gene signature with 730 regulated genes has
been reported. The gene cluster covers a broad range
of genes, but has a predicted pattern of genes related
to cellular motility. The signature of the human ho-
mologue genes has identified a subset of liver tumours
[hepatocellular carcinomas (HCCs)], in which the sig-
nature has a significant correlation with an increased
rate of vascular invasion and microvessel density and
a decreased mean survival time of HCC patients 11.
Other documented genes include those associ-
ated with the b-catenin pathway. Activation of cMet
is able to activate the b-catenin pathway, which in
turn activates transcription of the cell cycle regula-
tors (such as cyclins). As a result, a self-amplifying
cycle of unregulated growth in cancer cells is cre-
ated 12–14. The cMet complex may cooperate with
other signalling complexes—that is, epidermal
growth factor receptor, insulin-like growth factor re-
ceptor, and neurotrophin receptor complex—in regu-
lation of gene expression and cancer cell behaviours,
including cell motility 15–17.
One of the very few genes known to downregulate
the action of combined HGF and Met signalling in
cells is the mitogen-inducible gene 6 (MIG6—also
called gene 33 and receptor-associated late trans-
ducer). The MIG6 gene can be induced by HGF,
which in turn inhibits the intracellular activation of
met by HGF. Thus, MIG6 may be key to the self-
regulation of HGF signalling in a cell. However,
whether this mechanism is impaired in cancer remains
to be investigated.
The other negative regulator for met is the
NOTCH family. Comoglio’s group 19 has reported that
the NOTCH receptor may downregulate met (a pro-
cess that appears to occur at the transcription level).
And NOTCH suppresses HGF-dependent Ras sig-
nalling and impairs HGF-dependent cellular re-
sponses. In turn, met activation leads to transcriptional
induction of the NOTCH ligand Delta and the NOTCH
effector HES1, indicating that met is able to self-tune
its own protein levels and the ensuing biochemical
and biologic outputs by stimulation of the NOTCH
pathway. The Spry2 protein has also been reported
to inhibit HGF-related cell proliferation, anchorage-
independent cell growth, and migration in wound-
healing and in vitro invasion assays 20 . A
mitochondrial protein, Mimp, that HGF is able to
induce, results in growth arrest by attenuating the
downstream cMet-induced events in mammary can-
cer cells 21.
The HGF–cMet signalling and the HGF-regu-
lated genes present an opportunity in targeting and
pharmaceutical manipulation. In addition, molecular
complexes that inhibit cMet signalling may also pro-
vide a good opportunity for countering the action of
HGF in cancer.
HGF REGULATORS AND CANCER
The other aspect that has been considered from a tar-
geting and therapeutic point of view is the post-trans-
lation activation of HGF. First synthesis of HGF occurs
as a single chain that is biologically inactive. Activa-
tion of the inactive HGF (also known as pro-HGF) is
a highly regulated process that requires orchestration
of a number of enzymes. One of the most powerful
activators is the HGF activator, HGFA. Other activa-
tors include urokinase-type plasminogen activator,
injurin, and a number of other enzymes. A recent ad-
dition to the activator list is hepsin, which has been
found to be able to cleave HGF and generate bioactive
HGF 22,23. Interestingly, a number of proteins are
known to regulate the activity of HGFA. Matriptase, a
member of the TMPRSS family, is a known activator
of pro-HGFA. Inhibitors of HGFA (HAIs) are Kunitz-
domain-containing proteins that act to inhibit HGFA.
In clinical cancers, HGFA has been shown to be
elevated in cancer and cancer cells. Circulating lev-
els of HGFA are also high in patients with cancer 24.
In contrast, some reports have shown that HAIs areJIANG
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present at reduced levels in cancer. However, that
finding remains controversial, because in certain
tumours,  HAIs are found at a higher level. Matriptases,
primarily matriptase-1, have been shown to be present
at a high level in tumours 25.
In the cellular interaction between HGF and stro-
mal cells, conditioned medium from cancer cells has
recently been shown to be able to induce rapid clus-
tering of fibroblasts and to initiate a necrotic process.
The process leads to a rapid and substantial increase
in the production and secretion of bioactive HGF from
fibroblasts 26. The other HGFA inhibitor, HAI2, has
also been shown to be transcriptionally down-
regulated in cancer cells, which leads to activation of
Met signalling 27.
Thus, cancer involves autocrine and paracrine
loops, receptor activation and mutation, gene ampli-
fication, gene rearrangement, and aberrant HGF ac-
tivators and inhibitors, presenting a wide array of
therapeutic targets.
HGF AND ITS SIGNALLING COMPLEX AS
THERAPEUTIC TARGETS
Given the broad functional spectrum of HGF and its
receptor in cancer, targeting HGF, the HGF receptor,
and signalling events has been an attractive option
for cancer therapy. Therapeutic approaches have been
attempted by developing tools against HGF [neutral-
izing antibodies, antisense oligonucleotides,
ribozyme, short interfering RNA (siRNA), and HGF
regulators including HAIs], against cMet (HGF an-
tagonists, antibodies, small molecules, antisense,
ribozymes, siRNA, and non-specific inhibitors), and
against cMet signalling events (coincident with anti-
cMet methods), and finally by using HGF activation
inhibitors. In addition, methods to mobilize the an-
tagonistic intracellular events may also be consid-
ered. Targeting HGF and its receptor is particularly
attractive in cancer therapies, because HGF is a dual
player in the complex biology of cancer development
and progression: it acts directly on and stimulates
cancer cells, and it acts as an angiogenic factor and
lymphangiogenic factor that aid the growth and
spread of cancer cells.
These therapeutic approaches are largely in the
development phase, with a small number—mostly
non-specific inhibitors to cMet—now in early clini-
cal study. The list of these developments is beyond
the scope of the current article. However, some of
the early developments, such as the HGF antagonist
and small molecules, are anticipated to have an op-
portunity to make it into human-phase studies.
HGF AND ITS RECEPTOR AS IMAGING
TARGETS
The fact that the HGF receptor is highly overex-
pressed in cancer cells, and indeed well-expressed in
endothelial cells, has prompted interest in exploring
the receptor as potential tool for imaging. Conjugated
anti-cMet antibody has been reported to be able to
light up small tumours in vivo. If that result proves
valid in clinical settings, then a wider implication
arises: by conjugating therapeutic agents to the anti-
body, the technology might be used in diagnostic
imaging and in therapies. The conjugates will serve
as a delivery vehicle and at the same time as a recep-
tor-neutralizing agent (for a neutralizing antibody).
Using 125I-labelled anti-Met antibody in in vivo
models, the antibody has been shown to be enriched
in the met-positive tumour of lung cancer (SK-LMS-1
xenograft) 28, suggesting a possible diagnostic and
therapeutic advantage. Vande Woude’s group 29 has
developed a range of anti-Met antibodies for in vivo
imaging. In their recent report, tumours were shown
to exhibit rapid and sustained uptake of these 125I-
labelled antibodies, permitting detection of in vivo
tumours by a total-body gamma camera 29. Infusion
of HGF increases blood flow and oxygenation in or-
gans that have high levels of the HGF receptor and
in smaller vessels in tumours, suggesting a potential
use of functional molecular imaging in cancer 30.
One interesting challenge of using anti-cMet an-
tibody would be the presence of soluble cMet pro-
teins in the circulation because of shedding from
cancer cells. Ectodomain shedding of the HGF re-
ceptor has been recently reported 31. Shed receptor
can be detected in tumour-bearing plasma and in cell
culture supernatant, and is linked to tumour progres-
sion. Shedding may reflect the increased rate of re-
ceptor synthesis or of activation-enzyme activity in
cancer cells (or both), resulting in degradation of the
receptor. The presence of this circulating protein may
therefore impede the action and effectiveness of an-
tibodies raised against the extracellular domain of the
receptor.
PERSPECTIVES
It is compelling that HGF and its receptor are key
players in the development and, importantly, in the
progression of solid and blood-borne malignancies.
The cytokine and its receptor complex have signifi-
cant prognostic value in cancer. But despite all these
optimistic biologic and clinical aspects, it must be
borne in mind that HGF is one of the numerous pro-
tein factors associated with cancer and cancer pro-
gression. The unique niche for HGF is its double role
in cancer: direct action on cancer cells to increase
their aggressiveness, and direct action on endothe-
lial cells to induce angiogenesis and lymphangio-
genesis. This role makes HGF–cMet complex a
highly desirable target. Thus, beyond the complex’s
traditional prognostic and predictive value is the ap-
parent strong implication that HGF–cMet would be
a promising molecular target and molecular imaging
tool.HGF AND HGF RECEPTOR AS THERAPEUTIC TARGETS
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